Developer docs
API playgroundTry for free, no card

Search company profiles

Curematch

Full company profile

uuid0006mls

Namestring
Curematch
Legal namestring
CureMatch, Inc.
Websiteurl
curematch.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

CureMatch is a San Diego-based precision oncology company, founded in 2015, that builds a clinical Decision Support System for oncologists treating solid and hematologic cancers. The platform ingests patient molecular profiling data — DNA sequencing, RNA sequencing, protein expression, and other biomarker inputs — and runs proprietary Knowledge Representation & Reasoning (KRR) algorithms against more than 4.5 million drug combinations to produce scored and ranked 2-, 3-, and 4-drug personalized combination therapy recommendations. Reports are typically delivered within 72 hours, integrate on-label, off-label, and immunotherapies, and are agnostic to the upstream NGS/tumor-profiling vendor (with integrations or partnerships including Tempus, Foundation Medicine, Guardant Health, mProbe, and Paradigm). The American Medical Association issued CPT Code 0794T for the service in 2023, enabling payer claim submission and reimbursement tracking, though insurance does not currently reimburse the service as a covered benefit.

CureMatch monetizes primarily through quote-based enterprise contracts and recurring Decision Support System subscriptions sold to cancer centers, hospital systems, NGS labs, concierge medicine providers, and individual oncology practices; patients may pay out-of-pocket using FSA/HSA funds and a financial assistance program is offered, with free reports provided for children with cancer. The company also pursues BioPharma and employer channels for clinical-trial matching and cancer-care benefits. Customer logos include UC San Diego Health, Dignity Health, Memorial Care, Johns Hopkins Hospital, Hope Health Center, and Medical University of Graz. Operations are anchored in San Diego with international touchpoints in Mexico, the UAE, Portugal, and Austria.

The company is led by CEO and Co-Founder Navid Alipour, with Chief Medical Officer Dr. Razelle Kurzrock (UCSD Moores Cancer Center) and Chief Science Officer Dr. Igor Tsigelny (formerly San Diego Supercomputer Center) as co-founders, and Dr. Stephane Richard as COO. Funding history consists primarily of two 2017 bridge rounds (led by Serra Ventures with participation from Analytics Ventures, Hera Fund, Phil Trubey, and others) and modest MetroConnect export grants; the company has not disclosed a priced Series A or any institutional growth round in available data. Strategic priorities evidenced by recent activity — CPT coding, proteomics integration, the Mark Cuban Cost Plus Drug Company collaboration, and CancerX membership — center on scaling reimbursement, multi-omic depth, and ecosystem reach.

Short descriptiontext

CureMatch is a San Diego-based precision oncology company whose Decision Support System analyzes patient molecular profiles against 4.5M+ drug combinations to rank personalized cancer therapies for oncologists, cancer centers, and NGS labs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology, clinical decision support, combination therapy, molecular profiling, cancer treatment matching
Industry3 codes
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
Precision Oncology Decision Support
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Oncology Decision Support Reports
TypeSubscription Recurring
Description

CureMatch provides scored and ranked personalized combination therapy reports to oncologists for their patients. The company charges for its Decision Support System analysis services. Reports are submitted using CPT Code 0794T for reimbursement tracking, though insurance reimbursement is not currently available.

curematch.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Quote-based enterprise pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly listed. The service is available through oncologist request. Insurance does not currently reimburse CureMatch services, though CPT Code 0794T has been granted by AMA for tracking purposes.

curematch.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1CureMatch Certified Precision Oncology Recognition Award
Description

A recognition award program to honor oncology physicians who demonstrate exceptional commitment to advancing cancer care through next-generation sequencing (NGS) and precision medicine.

curematch.com
Core offering1 text field

CureMatch operates a cloud-based Decision Support System that ingests patient molecular profiling data (DNA/RNA sequencing, protein expression) and ranks over 4.5 million possible drug combinations to surface personalized combination therapy options for cancer patients. The system delivers scored, ranked 2-, 3-, and 4-drug combination reports to oncologists within 72 hours, integrating on-label and off-label FDA-approved oncology drugs including immunotherapies, targeted therapies, and hormone therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 75% of patients treated with combination therapies based on high CureMatch matching scores showed significantly improved progression-free survival
+3 more records
Product overview1 text field

CureMatch offers a unified precision oncology platform centered on its Decision Support System, which generates personalized combination therapy reports for oncologists. The core product analyzes molecular profiling data against over 4.5 million drug combinations to rank the most effective treatment options for individual cancer patients. The platform supports monotherapy and combination therapies of up to 4 drugs, delivers results within 72 hours, and is covered under CPT Code 0794T. CureMatch integrates genomic and proteomic data and considers immunotherapy, targeted therapy, hormone therapy, and newly approved oncology drugs in its recommendations.

Product and service2 records
1CureMatch Decision Support System
CategoryClinical Decision Support Software
Description

Cloud-based clinical decision support platform that analyzes patient molecular profiling data against more than 4.5 million drug combinations and produces ranked personalized combination therapy recommendations for oncologists and cancer centers.

2CureMatch Oncology Report
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-11-18
Description

Expanded partnership to assist US Special Operations Forces veterans with cancer in identifying targeted therapies and clinical trial options in New York.

Strategic tierStrategicTypeGTM or Marketing PartnerAnnounced on2023-10-01
Description

Collaboration to make cancer treatments more affordable and accessible. Patients with a CureMatch report can use Cost Plus Drugs to get lower prices on cancer medications in any combination treatment prescribed. Aligns with Cancer Moonshot initiative.

3CancerX
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Public-private partnership launched by The White House as national accelerator boosting innovation in fight against cancer as part of reignited Cancer Moonshot initiative.

curematch.com
4mProbe Inc.
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-03-01
Description

Partnership to leverage mProbe's targeted proteomics platform to assess individual proteins within patients' tumor tissues. mProbe is a CLIA-certified targeted proteomics company with proprietary technology.

curematch.com
5Center for Oncology in Pediatrics (COP), Mexico
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2018-06-01
Description

Global expansion partnership as part of MetroConnect award. Extending precision medicine technology for cancer treatment in Mexico.

curematch.com
Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-04-01
Description

Agreement to facilitate delivery of Personalized Combination Therapy options to global cancer care community. SOTERIA provides concierge precision medicine advisory and CureMatch evaluates patient sequencing data for ranked treatment options.

7Precision Medicine Leaders Summit
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2017-08-01
Description

CureMatch exhibited at the Precision Medicine Leaders Summit 2017 in San Diego, showcasing decision support system to precision medicine leaders.

curematch.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-04-01
Description

Selected to partner with JLABS-San Diego, a Johnson & Johnson Innovation Center. Provides access to state-of-the-art equipment, facilities and operations management on the Torrey Pines mesa near La Jolla.

9UC San Diego Moores Cancer Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding clinical partner where CureMatch was initially developed. Ongoing relationship for clinical validation, case studies, and research publications. Co-founder Dr. Razelle Kurzrock is from UCSD.

curematch.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Initial development partner for computational infrastructure. CureMatch approach was developed using supercomputing power and data analytics at SDSC.

11Tempus
Strategic tierCoreTypeTechnology or Integration
Description

Technology partner integration. CureMatch is agnostic to tumor profiling company data and works with Tempus molecular profiling results.

curematch.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Expanded partnership to assist US Special Operations Forces veterans with cancer in identifying targeted therapies and clinical trial options. Personalized cancer treatment options for veterans.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Technology partner listed on CureMatch website for pediatric applications.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Through Dubai Future Accelerators program, CureMatch worked with DHA during 12-week program to setup strategic partnerships with local healthcare institutions and implement precision medicine solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling and now bundles treatment-options reporting for oncologists. Directly comparable as a molecular profiling-plus-decision-support offering, though anchored on its own sequencing assays, of which CureMatch is a partner-channel consumer.

2Tempus
TypeDirect peer
Description

Tempus is an AI-driven precision medicine company combining molecular profiling with clinical decision support for oncology. Overlaps directly with CureMatch in offering oncologists treatment recommendations derived from multi-omic patient data, but Tempus operates its own sequencing lab vs. CureMatch's lab-agnostic model.

TypeBroad incumbent
Description

Flatiron Health (acquired by Roche) builds oncology-specific EHR data infrastructure and clinical decision support for cancer care providers. Broader incumbent scope (EHR, RWE, point-of-care) that intersects with CureMatch's physician-facing decision support.

TypeDirect peer
Description

Guardant Health is a leading liquid biopsy and molecular profiling company whose data feeds into CureMatch pipelines. Operates in precision oncology with treatment guidance capabilities, and is both a competitor in profiling-aware CDS and a CureMatch channel partner.

TypeEmerging player
Description

Syapse partners with health systems to operationalize precision oncology through real-world data and treatment decision workflows. Overlaps with CureMatch on precision-oncology decision support, but focused on broader data-platform deployment rather than per-patient ranking reports.

TypeDirect peer
Description

Caris offers multi-omic molecular profiling (DNA, RNA, protein) coupled with AI-driven treatment recommendations for oncologists. Highly comparable to CureMatch in integrating genomic and proteomic data to rank therapy options, while also running its own CLIA-certified lab.

TypeDirect peer
Description

Navican is an oncology decision-support and care-navigation service offering molecular tumor board reviews and therapy recommendations to oncologists. Closely comparable in workflow, target user, and clinical positioning to CureMatch's oncology reports.

TypeDirect peer
Description

Molecular Health provides genomics-based clinical decision support, including drug-response and combination analysis for oncologists. Comparable as a software-driven precision oncology CDS vendor with EMEA presence.

TypeBroad incumbent
Description

Philips offers evidence-based oncology treatment pathways and clinical decision support embedded in oncology workflows. Broader incumbent with enterprise-wide CDS vs. CureMatch's niche molecular-combination ranking focus.

10N-of-One / QIAGEN Clinical Insights
TypeDirect peer
Description

N-of-One was a molecular decision-support service matching tumor profiles to therapies and clinical trials; it was acquired by QIAGEN and integrated into QIAGEN Clinical Insights. Directly comparable to CureMatch as interpretation/decision-support atop molecular profiling data.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curematch

Precision Oncology Decision Supportcurematch.com

CureMatch is a San Diego-based precision oncology company whose Decision Support System analyzes patient molecular profiles against 4.5M+ drug combinations to rank personalized cancer therapies for oncologists, cancer centers, and NGS labs.

What Curematch does

CureMatch is a San Diego-based precision oncology company, founded in 2015, that builds a clinical Decision Support System for oncologists treating solid and hematologic cancers. The platform ingests patient molecular profiling data — DNA sequencing, RNA sequencing, protein expression, and other biomarker inputs — and runs proprietary Knowledge Representation & Reasoning (KRR) algorithms against more than 4.5 million drug combinations to produce scored and ranked 2-, 3-, and 4-drug personalized combination therapy recommendations. Reports are typically delivered within 72 hours, integrate on-label, off-label, and immunotherapies, and are agnostic to the upstream NGS/tumor-profiling vendor (with integrations or partnerships including Tempus, Foundation Medicine, Guardant Health, mProbe, and Paradigm). The American Medical Association issued CPT Code 0794T for the service in 2023, enabling payer claim submission and reimbursement tracking, though insurance does not currently reimburse the service as a covered benefit.

CureMatch monetizes primarily through quote-based enterprise contracts and recurring Decision Support System subscriptions sold to cancer centers, hospital systems, NGS labs, concierge medicine providers, and individual oncology practices; patients may pay out-of-pocket using FSA/HSA funds and a financial assistance program is offered, with free reports provided for children with cancer. The company also pursues BioPharma and employer channels for clinical-trial matching and cancer-care benefits. Customer logos include UC San Diego Health, Dignity Health, Memorial Care, Johns Hopkins Hospital, Hope Health Center, and Medical University of Graz. Operations are anchored in San Diego with international touchpoints in Mexico, the UAE, Portugal, and Austria.

The company is led by CEO and Co-Founder Navid Alipour, with Chief Medical Officer Dr. Razelle Kurzrock (UCSD Moores Cancer Center) and Chief Science Officer Dr. Igor Tsigelny (formerly San Diego Supercomputer Center) as co-founders, and Dr. Stephane Richard as COO. Funding history consists primarily of two 2017 bridge rounds (led by Serra Ventures with participation from Analytics Ventures, Hera Fund, Phil Trubey, and others) and modest MetroConnect export grants; the company has not disclosed a priced Series A or any institutional growth round in available data. Strategic priorities evidenced by recent activity — CPT coding, proteomics integration, the Mark Cuban Cost Plus Drug Company collaboration, and CancerX membership — center on scaling reimbursement, multi-omic depth, and ecosystem reach.

Curematch firmographics

Firmographics
Name
Curematch
Legal name
CureMatch, Inc.
Website
https://curematch.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
CureMatch is a San Diego-based precision oncology company whose Decision Support System analyzes patient molecular profiles against 4.5M+ drug combinations to rank personalized cancer therapies for oncologists, cancer centers, and NGS labs.
Ownership category
akta.pro rank

Curematch industry classification

Industry
Product category
Precision Oncology Decision Support
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)

Keywords

  • Precision oncology
  • Clinical decision support
  • Combination therapy
  • Molecular profiling
  • Cancer treatment matching

Where Curematch is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Curematch business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Oncology Decision Support Reports: CureMatch provides scored and ranked personalized combination therapy reports to oncologists for their patients. The company charges for its Decision Support System analysis services. Reports are submitted using CPT Code 0794T for reimbursement tracking, though insurance reimbursement is not currently available.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Curematch product offering

Product offering

Core offering

CureMatch operates a cloud-based Decision Support System that ingests patient molecular profiling data (DNA/RNA sequencing, protein expression) and ranks over 4.5 million possible drug combinations to surface personalized combination therapy options for cancer patients. The system delivers scored, ranked 2-, 3-, and 4-drug combination reports to oncologists within 72 hours, integrating on-label and off-label FDA-approved oncology drugs including immunotherapies, targeted therapies, and hormone therapies.

Product overview

CureMatch offers a unified precision oncology platform centered on its Decision Support System, which generates personalized combination therapy reports for oncologists. The core product analyzes molecular profiling data against over 4.5 million drug combinations to rank the most effective treatment options for individual cancer patients. The platform supports monotherapy and combination therapies of up to 4 drugs, delivers results within 72 hours, and is covered under CPT Code 0794T. CureMatch integrates genomic and proteomic data and considers immunotherapy, targeted therapy, hormone therapy, and newly approved oncology drugs in its recommendations.

Differentiator

Problem solved

Functional benefit

Brands

  • CureMatch Certified Precision Oncology Recognition Award: A recognition award program to honor oncology physicians who demonstrate exceptional commitment to advancing cancer care through next-generation sequencing (NGS) and precision medicine.

Products and services

  • CureMatch Decision Support System Cloud-based clinical decision support platform that analyzes patient molecular profiling data against more than 4.5 million drug combinations and produces ranked personalized combination therapy recommendations for oncologists and cancer centers.
  • CureMatch Oncology Report

Quantifiable outcome

  • 75% of patients treated with combination therapies based on high CureMatch matching scores showed significantly improved progression-free survival
  • +3 more outcomes

Companies that use Curematch

Customer profile

Named customers7 records

Segments6 records

Ideal customer profiles4 records

Curematch technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Curematch partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered strategic, core and minor.

  • Soteria Precision Medicine Foundation (Veteran Partnership)strategicStrategic or Co-development Partner · 18 November 2025Expanded partnership to assist US Special Operations Forces veterans with cancer in identifying targeted therapies and clinical trial options in New York.
  • Mark Cuban Cost Plus Drug CompanystrategicGTM or Marketing Partner · 1 October 2023Collaboration to make cancer treatments more affordable and accessible. Patients with a CureMatch report can use Cost Plus Drugs to get lower prices on cancer medications in any combination treatment prescribed. Aligns with Cancer Moonshot initiative.
  • CancerXstrategicStrategic or Co-development Partner · 1 June 2023Public-private partnership launched by The White House as national accelerator boosting innovation in fight against cancer as part of reignited Cancer Moonshot initiative.
  • mProbe Inc.coreTechnology or Integration · 1 March 2023Partnership to leverage mProbe's targeted proteomics platform to assess individual proteins within patients' tumor tissues. mProbe is a CLIA-certified targeted proteomics company with proprietary technology.
  • Center for Oncology in Pediatrics (COP), MexicostrategicStrategic or Co-development Partner · 1 June 2018Global expansion partnership as part of MetroConnect award. Extending precision medicine technology for cancer treatment in Mexico.
  • SOTERIA Precision Medicine Advisory, Inc.strategicChannel Partner/ Reseller/ Distributor · 1 April 2018Agreement to facilitate delivery of Personalized Combination Therapy options to global cancer care community. SOTERIA provides concierge precision medicine advisory and CureMatch evaluates patient sequencing data for ranked treatment options.
  • Precision Medicine Leaders SummitminorGTM or Marketing Partner · 1 August 2017CureMatch exhibited at the Precision Medicine Leaders Summit 2017 in San Diego, showcasing decision support system to precision medicine leaders.
  • JLABS-San Diego (Johnson & Johnson)coreStrategic or Co-development Partner · 1 April 2016Selected to partner with JLABS-San Diego, a Johnson & Johnson Innovation Center. Provides access to state-of-the-art equipment, facilities and operations management on the Torrey Pines mesa near La Jolla.
  • UC San Diego Moores Cancer CentercoreStrategic or Co-development PartnerFounding clinical partner where CureMatch was initially developed. Ongoing relationship for clinical validation, case studies, and research publications. Co-founder Dr. Razelle Kurzrock is from UCSD.
  • San Diego Supercomputer CentercoreStrategic or Co-development PartnerInitial development partner for computational infrastructure. CureMatch approach was developed using supercomputing power and data analytics at SDSC.
  • TempuscoreTechnology or IntegrationTechnology partner integration. CureMatch is agnostic to tumor profiling company data and works with Tempus molecular profiling results.
  • Soteria Precision Medicine FoundationstrategicStrategic or Co-development PartnerExpanded partnership to assist US Special Operations Forces veterans with cancer in identifying targeted therapies and clinical trial options. Personalized cancer treatment options for veterans.
  • Rady Children's HospitalminorStrategic or Co-development PartnerTechnology partner listed on CureMatch website for pediatric applications.
  • Dubai Health AuthoritystrategicStrategic or Co-development PartnerThrough Dubai Future Accelerators program, CureMatch worked with DHA during 12-week program to setup strategic partnerships with local healthcare institutions and implement precision medicine solutions.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Curematch competitors and assessment

Company assessment

Direct peers

  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling and now bundles treatment-options reporting for oncologists. Directly comparable as a molecular profiling-plus-decision-support offering, though anchored on its own sequencing assays, of which CureMatch is a partner-channel consumer.
  • Tempus: Tempus is an AI-driven precision medicine company combining molecular profiling with clinical decision support for oncology. Overlaps directly with CureMatch in offering oncologists treatment recommendations derived from multi-omic patient data, but Tempus operates its own sequencing lab vs. CureMatch's lab-agnostic model.
  • Guardant Health: Guardant Health is a leading liquid biopsy and molecular profiling company whose data feeds into CureMatch pipelines. Operates in precision oncology with treatment guidance capabilities, and is both a competitor in profiling-aware CDS and a CureMatch channel partner.
  • Caris Life Sciences: Caris offers multi-omic molecular profiling (DNA, RNA, protein) coupled with AI-driven treatment recommendations for oncologists. Highly comparable to CureMatch in integrating genomic and proteomic data to rank therapy options, while also running its own CLIA-certified lab.
  • Navican (Intermountain Healthcare): Navican is an oncology decision-support and care-navigation service offering molecular tumor board reviews and therapy recommendations to oncologists. Closely comparable in workflow, target user, and clinical positioning to CureMatch's oncology reports.
  • Molecular Health: Molecular Health provides genomics-based clinical decision support, including drug-response and combination analysis for oncologists. Comparable as a software-driven precision oncology CDS vendor with EMEA presence.
  • N-of-One / QIAGEN Clinical Insights: N-of-One was a molecular decision-support service matching tumor profiles to therapies and clinical trials; it was acquired by QIAGEN and integrated into QIAGEN Clinical Insights. Directly comparable to CureMatch as interpretation/decision-support atop molecular profiling data.

Broad incumbents

  • Flatiron Health: Flatiron Health (acquired by Roche) builds oncology-specific EHR data infrastructure and clinical decision support for cancer care providers. Broader incumbent scope (EHR, RWE, point-of-care) that intersects with CureMatch's physician-facing decision support.
  • Philips Oncology Pathways: Philips offers evidence-based oncology treatment pathways and clinical decision support embedded in oncology workflows. Broader incumbent with enterprise-wide CDS vs. CureMatch's niche molecular-combination ranking focus.

Emerging players

  • Syapse: Syapse partners with health systems to operationalize precision oncology through real-world data and treatment decision workflows. Overlaps with CureMatch on precision-oncology decision support, but focused on broader data-platform deployment rather than per-patient ranking reports.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Curematch social profiles

Digital presence

Curematch compliance and trust

Trust signal

Compliance1 record

Curematch financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curematch leadership team

Management profile

Number of profiles

Profiles7 records

Curematch funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curematch M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curematch

What does Curematch do?

CureMatch operates a cloud-based Decision Support System that ingests patient molecular profiling data (DNA/RNA sequencing, protein expression) and ranks over 4.5 million possible drug combinations to surface personalized combination therapy options for cancer patients. The system delivers scored, ranked 2-, 3-, and 4-drug combination reports to oncologists within 72 hours, integrating on-label and off-label FDA-approved oncology drugs including immunotherapies, targeted therapies, and hormone therapies.

Is Curematch a public or private company?

Curematch is a private company. It is classified as venture growth investor backed and is currently operating.

When was Curematch founded?

Curematch was founded in 2015. It employs 11 to 50 people.

Where is Curematch based?

Curematch is headquartered in San Diego, United States, in the North America region.

How does Curematch make money?

One revenue line is on record: oncology Decision Support Reports.

Who are Curematch's main competitors?

Direct peers on record are Foundation Medicine, Tempus, Guardant Health, Caris Life Sciences, Navican (Intermountain Healthcare), Molecular Health and N-of-One / QIAGEN Clinical Insights. Broad incumbents are Flatiron Health and Philips Oncology Pathways. Syapse is listed as an emerging player.

Does Curematch have an API?

No public API is recorded for Curematch.

What industry is Curematch in?

Curematch's product category is Precision Oncology Decision Support. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSOTERIA and CureMatch Expand Collaboration to Advance Precision Oncology for U.S. Special Operations Forces Battling CancerSOTERIA Precision Medicine Foundation and CureMatch, Inc. announced an expanded collaboration to provide personalized cancer treatment insights to U.S. Special Operations Forces veterans. The partnership integrates SOTERIA's precision medicine navigation with CureMatch's AI-powered predictive analytics to help clinicians identify targeted therapies and clinical trial opportunities for this patient group.LA Business JournalQuantgene Teams With Cancer Therapy Guidance CompanySanta Monica-based Quantgene Inc. and San Diego-based CureMatch Inc. announced a partnership on March 24 to combine their artificial intelligence technologies for cancer diagnosis and treatment guidance. The collaboration aims to provide oncologists with comprehensive molecular tumor profiles and personalized treatment recommendations derived from blood samples and tumor data. This agreement marks Quantgene's third partnership announcement in the past year, following collaborations with Phosphorus Inc. and DNAVisit.PR NewswireQuantgene and CureMatch Announce Strategic Partnership To Help Cancer Patients Find the Best Precision TreatmentQuantgene, Inc. and CureMatch, Inc. have announced a strategic partnership to combine their genomic, cloud, and AI technologies for improving precision cancer treatments. The integrated solution merges Quantgene's liquid biopsy technology with CureMatch's clinical decision support system, allowing cancer patients to receive matched therapy recommendations from a simple blood draw within three weeks. The companies will also collaborate on advancing genomics and AI-guided oncology solutions to expand access to precision medicine.PrwebCureMatch Named Winner: Best Technological Innovation: DigitalCureMatch was named the winner of the Best Technological Innovation: Digital category at the MedTech Insight Awards 2019. Judges recognized the company's platform for its potential to transform cancer care through data-driven personalized medicine. CureMatch CEO Bob Manning accepted the award, highlighting the team's effort in empowering oncologists with actionable intelligence.PR NewswireCureMatch Hires Associate Vice President of Clinical OperationsCureMatch, a San Diego-based digital health company focused on personalized oncology medicine, announced the hire of Yekaterina Khotskaya as Associate Vice President of Clinical Operations. Khotskaya brings experience in precision oncology research, software development, and molecular diagnostics, having previously served as a fellow at MD Anderson's Institute for Personalized Cancer Therapy and worked at QIAGEN Bioinformatics. The CEO cited her unique combination of skills in personalized medicine and software as key to advancing CureMatch's clinical operations.San Diego Business JournalFrench Pharmaceutical Giant Partners with CureMatchServier Group has partnered with CureMatch to support and market the startup's oncology software through its WeHealth brand, providing CureMatch with global sales and marketing infrastructure. The collaboration aims to expand access to personalized cancer treatment options by leveraging Servier's presence in 148 countries.San Diego Business JournalCureMatch Takes Home MetroConnect PrizeCureMatch received the $35,000 MetroConnect Prize to fund free cancer treatment services for children at a clinic in Tijuana. The award is part of the startup's broader export strategy supported by the World Trade Center San Diego program. CureMatch uses AI to help oncologists select optimal treatments from millions of options.PR NewswireCureMatch Presents PreciGENE™ Performance Results at AACR Annual MeetingCureMatch, Inc. presented new data at the American Association for Cancer Research Annual Meeting in Chicago on April 16, 2018, showcasing validation results for its PreciGENE therapeutic decision-support system in precision oncology. A retrospective analysis of 70 cancer patients with 202 treatment lines found that the platform correctly predicted treatment response in nearly 80% of cases (161 out of 202 regimens), with significantly higher matching scores for regimens that led to positive outcomes compared to those that failed. The platform, developed through collaboration between CureMatch, UC San Diego, and the San Diego Super-Computer Center, analyzes molecular profiles to guide oncologists in selecting personalized cancer treatment combinations.PR NewswireCo-Founder of CureMatch® Precision Oncology Technology is Co-Author in Cancer Discovery JournalIgor F. Tsigelny, Co-founder and Chief Technology Officer at CureMatch, co-authored a study published in Cancer Discovery journal comparing liquid biopsy techniques using cell-free DNA (cfDNA) versus direct tumor sequencing in 1,397 colorectal cancer patients. The study found that liquid biopsy detected genomic alterations at frequencies comparable to tissue biopsy while also identifying new mutations and offering insights into tumor therapeutic resistance. The results suggest cfDNA profiling can effectively define the genomic landscape of cancer, providing a less invasive and less expensive alternative to traditional tissue biopsies.PR NewswireOncologists Can Now Specify Cancer Treatment Options to Score and Rank with CureMatchCureMatch announced a new release of its PreciGENE technology at the Biotech Showcase 2018, enabling oncologists to input specific drug therapies to score and rank against millions of potential treatment options. The system analyzes patient tumor profiling data to generate personalized combination therapy recommendations based on molecular biomarker profiles.